Estrogen Receptor-Mediated Vascular Responsiveness to Nebivolol: A Novel Endothelium-Related Mechanism of Therapeutic Vasorelaxation

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 5, 2004, Pages 638-644

  Garbán, Hermes J ^a   Buga, Georgette M ^a   Ignarro, Louis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Estrogen; Estrogen receptor; Nebivolol; Nitric oxide; Vascular endothelium

Indexed keywords

ANTIESTROGEN; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ESTROGEN RECEPTOR; FULVESTRANT; NEBIVOLOL; NITRIC OXIDE;

ANIMAL TISSUE; ARTICLE; BINDING KINETICS; CELL MEMBRANE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; HYPOTHESIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION;

ANIMALS; AORTA, THORACIC; BENZOPYRANS; BINDING, COMPETITIVE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR BETA; ETHANOLAMINES; HUMANS; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION; VASODILATOR AGENTS;

EID: 2042454990     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200405000-00005     Document Type: Article

References (38)

1. Gao YS, Nagao T, Bond RA, et al. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol. 1991;17:964-969.
2. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol. 1994;38:199-204.
3. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
4. Dawes M, Brett SE, Chowienczyk PJ, et al. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol. 1999;48:460-463.
5. Pietras RJ, Szego CM. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature. 1977;265:69-72.
6. Pietras RJ, Szego CM. Partial purification and characterization of oestrogen receptors in subfractions of hepatocyte plasma membranes. Biochem J. 1980;191:743-760.
7. Wyckoff MH, Chambliss KL, Mineo C, et al. Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Gα(i). J Biol Chem. 2001:276:27071-27076.
8. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 2000;87:677-682.
9. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
10. Mendelsohn ME. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean? Circ Res. 2000;87:956-960.
11. 2+ mobilization. Circ Res. 1997;81:885-892.
12. 1-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide. 2002;7:75-82.
13. Buga GM, Griseavage JM, Rogers NE, et al. Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res. 1993;73:808-812.
14. Marquez DC, Pietras RJ. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene. 2001;20:5420-5430.
15. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
16. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J. 1989;3:2007-2018.
17. Parenti A, Filippi S, Amerini S, et al. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther. 2000;292:698-703.
18. Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol. 2001;38(Suppl 3):S13-S16.
19. Barton M, Cremer J, Mugge A. 17Beta-estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries. Eur J Pharmacol. 1998;362:73-76.
20. Mangrella M, Rossi F, Fici F. Pharmacology of nebivolol. Pharmacol Res. 1998;38:419-431.
21. Yusuf S, Garg R. Randomized trials to assess the long-term effects of therapies on angiographic end points. Chest. 1991;99:1243-1247.
22. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1988;260:2088-2093.
23. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5:561-572.
24. Koch-Weser J, Frishman WH. beta-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981;305:500-506.
25. Sponer G, Bartsch W, Strein K. Pharmacological profile of beta-adrenoceptor blockers with vasodilating properties, especially carvedilol-rationale for clinical use. Clin Investig. 1992;70(Suppl 1):S20-S26.
26. Hampton JR. Choosing the right beta-blocker. A guide to selection. Drugs. 1994;48:549-568.
27. Pauwels PJ, Gommeren W, Van Lommen G, et al. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol. 1988;34:843-851.
28. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs. 1999;57:633-651.
29. Van de Water A, Janssens W, Van Neuten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol. 1988;11:552-563.
30. Janssens WJ, Van de Water A, Xhonneux R, et al. Nebivolol is devoid of intrinsic sympathomimetic activity. Eur J Pharmacol. 1989;159:89-95.
31. Chlopicki S, Lomnicka M, Gryglewski RJ. Reversal of the postischaemic suppression of coronary function in perfused guinea pig heart by ischaemic preconditioning. J Physiol Pharmacol. 1999;50:605-615.
32. Gosgnach W, Boixel C, Nevo N, et al. Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-adrenergic pathway. J Cardiovasc Pharmacol. 2001:38:191-199.
33. Kakoki M, Hirata Y, Hayakawa H, et al. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension. 1999;33:467-471.
34. Chlopicki S, Kozlovski VI, Gryglewski RJ. NO-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors. J Physiol Pharmacol. 2002;53:615-624.
35. Gilligan DM, Quyyumi AA, Cannon RO 3rd. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 1994;89:2545-2551.
36. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000;407:538-541.
37. Simoncini T, Rabkin E, Liao JK. Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:198-203.
38. Simoncini T, Fornari L, Mannella P, et al. Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase. Steroids. 2002;67:935-939.